Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TG-2349 + DAG181 in Treatment-Naïve HCV Genotype 1
NCT03593447Phase 2Completed
- Sponsor
- Dongguan HEC TaiGen Biopharmaceuticals
- Start
- Mar 2018
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of furaprevir, yimitasvir in hepatitis C (HCV), sponsored by Dongguan HEC TaiGen Biopharmaceuticals. Started Mar 2018; status: completed.
02
Drugs
furapreviryimitasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03593447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03593447.